AG真人官方

NOVA Ltd. (NVMI) has filed a Form 144 indicating a planned sale of insider shares. The filing covers 1,390 ordinary shares to be sold through Oppenheimer & Co. on or after 30 June 2025. At the stated aggregate market value of $372,019.60, the implied per-share price is approximately $267. The company reports 29.28 million shares outstanding, so the proposed sale represents roughly 0.005 % of total shares鈥攁n immaterial fraction in ownership terms.

The seller鈥攊dentified in the past-three-month sales table as Simon Zehava鈥攈as already sold 855 shares over the previous week (24 & 26 June 2025) for combined gross proceeds of $221,040. The shares being sold were originally acquired on 25 June 2020 as Restricted Stock Units issued by NOVA. No cash consideration or 10b5-1 plan details are disclosed in the filing.

Because Form 144 is a notice rather than a completed transaction, the sale may or may not be executed depending on market conditions. Given the very small size relative to the float and the absence of material adverse information in the filing, the event is unlikely to have a meaningful impact on NOVA鈥檚 share price or fundamentals.

Nova Ltd Director Simon Zehava has filed Form 144 indicating a proposed sale of 720 ordinary shares with an aggregate market value of $183,852. The sale is planned to execute on June 26, 2025 through Oppenheimer & Co. Inc. on the Nasdaq exchange.

The shares were originally acquired on June 17, 2019, as Restricted Stock Units from the issuer. The filing reveals this sale is being conducted under a 10b5-1 trading plan adopted on December 2, 2024.

Recent trading activity shows Zehava previously sold 135 ordinary shares on June 24, 2025, for gross proceeds of $32,400. The company currently has 29,278,401 shares outstanding.

This planned transaction represents a relatively small portion of Nova's total outstanding shares and is being executed through a pre-planned trading arrangement, suggesting a routine insider sale rather than a significant strategic divestment.

Nova Ltd. (ticker NVMI) has filed a Form 144 with the U.S. Securities and Exchange Commission disclosing a planned sale of 2,051 ordinary shares. The shares will be sold through Oppenheimer & Co. Inc. on or about 25 June 2025 on the Nasdaq exchange. The filing assigns an aggregate market value of approximately US$509,714 to the proposed transaction, implying a reference price of roughly $248/share. Nova reports a total of 29,278,401 shares outstanding, so the planned sale represents only about 0.007 % of the float.

The seller previously disposed of 1,000 ordinary shares on 11 June 2025 for gross proceeds of US$235,000, indicating recent activity under Rule 144. Acquisition data show the shares originated from restricted stock unit (RSU) grants dated 31 Oct 2018 (730 sh), 6 Nov 2019 (664 sh) and 11 Nov 2020 (867 sh). No cash consideration or gifting was involved in the original awards.

The notice includes the standard representation that the seller is not in possession of undisclosed material adverse information. No Rule 10b5-1 plan date is provided, and no remarks were added by the filer.

For investors, the filing signals a modest insider monetisation event but, given its de-minimis size relative to the total share count, it is unlikely to have a material impact on Nova鈥檚 share-price dynamics.

On 26 June 2025, Terns Pharmaceuticals (TERN) filed a Form 4 disclosing that Chief Executive Officer and Director Amy L. Burroughs purchased 23,314 shares of common stock on 25 June 2025 at an average price of $3.8702 per share. The open-market buy represents an investment of roughly $90 thousand and lifts Burroughs鈥� direct holdings to 47,083 shares.

The filing contains no sales or derivative transactions. A footnote states that the total includes 4,160 shares previously acquired under the company鈥檚 2021 Employee Stock Purchase Plan on 31 May 2025.

CEO insider buying is often interpreted by investors as a vote of confidence in the company鈥檚 outlook. Although the dollar amount is modest, the transaction nearly doubles the CEO鈥檚 stake and occurs while TERN trades below $4, suggesting management perceives the shares to be undervalued.

Freedom Holding Corp. (FRHC) 鈥� Insider Transaction Summary

On 06/20/2025, President and Director Askar Tashtitov filed a Form 4 disclosing an open-market purchase of 600 FRHC common shares at a weighted-average price of $140.75, representing roughly $84,450 in total consideration. After the transaction, Tashtitov directly holds 137,208 shares of the company鈥檚 stock.

No derivative positions were reported, and the filing does not indicate that the trade was conducted under a Rule 10b5-1 plan. The transaction slightly increases the insider鈥檚 already significant equity stake and reaffirms ongoing Section 16 reporting obligations.